Business

Know the Business: Sonova Holding AG

Figures converted from Swiss francs at historical FX rates — see data/company.json.fx_rates for the rate table. Ratios, margins, and multiples are unitless and unchanged.

Sonova is the global leader in hearing care — it designs the aid, makes the chip inside it, and increasingly owns the shop that fits it. Strip away the corporate labels and you are buying one franchise: a high-margin Wholesale device business (Phonak, Unitron) fused to a sticky Retail audiology network (AudioNova), together earning a near-24% operating margin. Bolted on is a small, currently loss-making cochlear-implant unit (Advanced Bionics), and — as of March 2026 — a consumer-audio business on its way out the door [1]. The job of this tab is to show where the profit really comes from, how durable it is, and how an intelligent investor should underwrite it.

The verdict

Source: FY2025/26 Annual Report, Financial Review and Five-Year Key Figures [2] [3].

1. The economic engine: two businesses stapled together

Newcomers assume a "hearing-aid company" is one thing. It is two, reported inside a single segment. Wholesale designs and builds the device and sells it to independent audiologists, third-party chains, and government buyers — a technology race with high gross margins and product-cycle economics. Retail is the opposite: the AudioNova store network that tests, fits, tunes and services the device over years — local, relationship-heavy, and the stickier profit pool. Together they form the Hearing Instruments segment. A separate, much smaller Cochlear Implants segment (Advanced Bionics) serves severe-to-profound loss [4].

Source: FY2025/26 Annual Report — Hearing Instruments split of $2,348.7m Wholesale (56%) and $1,882.0m Retail (44%); Cochlear Implants $318.0m [5].

The Wholesale business grew 9.5% in local currency in FY2025/26, Retail 5.1% — both driven by share gains from a strong product cycle [6]. The vertical integration is the point: when a manufacturer owns the store, it captures both the device margin and the fitting margin, and it locks in a channel for its own brands. That is why Sonova calls itself "vertically integrated across Wholesale, Retail and Cochlear Implants" and runs the brands Phonak, Unitron, AudioNova and Advanced Bionics [7].

2. Where the profit actually comes from

This is the single most important thing to understand about valuing Sonova: essentially all of the profit is Hearing Instruments. The table below shows the two segments side by side for FY2025/26.

Source: FY2025/26 Annual Report — Hearing Instruments normalized EBITA $1,001.3m at a 23.7% margin; Cochlear Implants normalized EBITA $21.7m (6.8% margin) but a reported EBITA loss of $43.6m after legal and legacy product-liability charges [8].

Two takeaways. First, the Hearing Instruments franchise is exceptional — a 23.7% operating margin on a device-plus-service business is medtech-grade profitability, and it is rising (from 22.6% a year earlier) as Retail cost-efficiency work drops through [9]. Second, Cochlear Implants is currently a drag, not an engine. At 7% of sales it lost money at the reported level in FY2025/26: China's volume-based procurement (VBP) reset gutted pricing, and the largest implant competitor (Cochlear Limited) launched a new system in developed markets that took share [10]. Excluding China, implant system sales were roughly flat. Management guides to a second-half FY2026/27 pick-up once a new sound processor launches, subject to approval [11].

The practical implication for an investor: you are underwriting the Hearing Instruments business, and getting a Cochlear Implants turnaround option for free (or for a small negative today). Any sum-of-the-parts should value HI on medtech-compounder multiples and treat CI as a separate, lower-quality, option-like line.

3. The moat: silicon + audiology + channel

Sonova's competitive advantage rests on three reinforcing layers, and it is worth being precise about the mechanism of each.

1. Owning the whole technology stack. A modern premium hearing aid runs real-time deep neural networks on a proprietary chip small enough to sit behind an ear. Sonova designs its own AI chips, software, training pipeline and real-world-data feedback loop end to end — a capability only a handful of firms can fund [12]. The proof is in the current cycle: the Phonak Infinio / Sphere platform sold more than 1.5 million units in its first 12 months — the most successful launch in Sonova's history — with Sphere (the flagship AI variant) taking roughly half of platform sales [13]. Sonova frames Sphere as a genuine breakthrough — the first real-time, large-scale DNN that isolates and re-integrates speech in noise — versus "incremental AI from peers" on the industry's number-one unmet need [14].

2. Winning the product cycle drives share. Share in this oligopoly shifts with silicon. The new Virto R Infinio rechargeable in-the-ear device redefined the custom ITE category and, within a year, both grew Sonova's share of it and expanded the category itself — a market Sonova sizes at over $500 million of incremental opportunity growing 6–8% a year, faster than the overall market [15] [16]. It also swung the single most important institutional channel: Sonova's rechargeable custom device took around 60% of the US Department of Veterans Affairs in-the-ear segment, pushing overall VA share to a five-year high [17].

3. Owning the customer relationship. The AudioNova retail network — 811 stores, anchored by 70 "World of Hearing" flagships across 16 countries that generate roughly twice the sales of a standard location — turns a one-off device sale into a multi-year service relationship and feeds real fitting data back into R and D [18].

The honest read on the moat. It is real but not absolute. The technology and audiology barriers are high, but share is contestable every product cycle — the same mechanism that let Sonova take VA share can reverse when a rival ships better silicon. And the moat is weakest exactly where growth is fastest: the mild-loss / OTC end, where Sonova concluded its own Consumer Hearing bet was non-core and chose to exit rather than defend [19].

4. The cycle and the currency — reading the headline right

FY2025/26 is a masterclass in why you cannot read Sonova off its reported Swiss-franc numbers. Group sales were $4,549 million — up 5.9% in local currency but down 0.2% in francs, because a strong franc stripped out around $279 million of translated revenue (a 6.1-point drag in franc terms) [20]. Reported franc revenue looks stagnant for four years; the underlying business grew and the mix improved. (Translated into dollars, the same franc strength does the reverse — it lifts the reported figure — which is exactly why the USD view of this Swiss company is arguably the truer one.)

Source: FY2025/26 Annual Report, Five-Year Key Figures, converted to USD at period-end rates (2024/25 and 2025/26 on a continuing-operations basis, excluding the divested Consumer Hearing business) [21].

Source: FY2025/26 Annual Report, Five-Year Key Figures [22].

Margins peaked in the COVID-inflated FY2021/22 (24.7% normalized) and gave back ground as the market normalized, costs rose and the Cochlear drag widened — but the FY2025/26 rebound to a 22.5% normalized EBITA margin shows the operating leverage is intact once volume returns [23]. The cyclical judgment for the sector is simple: a hearing aid is a discretionary, big-ticket, often out-of-pocket purchase, so demand tracks consumer confidence. The market grew below trend through 2025; Sonova guides to only 2–4% market growth in FY2026/27, recovering toward its 3–5% mid-term assumption [24]. Call it moderate cyclicality on a secular-growth backbone.

A structural currency point worth holding onto: Sonova sells in EUR/USD/other but keeps only ~1% of sales and ~15% of its cost base in francs, and is actively cutting the franc cost share toward under 10% to widen its natural hedge — so a strong franc is a translation headwind, not an economic one [25]. For a global reader, the USD view of this company is arguably the truer one.

Geographic mix

Source: FY2025/26 Annual Report — EMEA 53% (+4.8% LC), USA 30% (+9.1% LC), Asia/Pacific 10% (+1.4% LC, held back by the China cochlear-implant weakness); converted to USD at the period-end rate [26].

Sonova is a developed-market franchise — EMEA and the USA are 83% of sales — with the fastest structural upside (and today's sharpest pain) in Asia. The US led growth at 9.1% on Wholesale and VA share gains; Asia lagged on the China implant reset [27].

5. Returns, cash and capital allocation

This is a genuinely cash-generative, capital-light business. Management's own 2021–2025 scorecard: high-single-digit local-currency sales CAGR, an average Core EBIT margin above 20%, roughly 90% cash conversion, and 18–20% ROCE on a balance sheet held at 1.0–1.5x net debt/EBITDA [28]. FY2025/26 delivered ROCE of 19.0%, net debt down to $1,254 million (1.1x EBITDA) and a 46.8% equity ratio [29].

The capital-allocation framework is disciplined and shareholder-friendly, in a clear priority order: fund organic growth and R and D first; spend $101–126 million a year on bolt-on retail acquisitions to scale the store footprint; pay a dividend at a ~40% payout ratio; keep leverage at 1.0–1.5x; and return surplus via buyback [30]. The dividend has compounded steadily to $5.93 for FY2025/26, and the company completed a $1.6 billion buyback program that ran 2022–2025 (nothing repurchased in FY2025/26) [31] [32].

Source: FY2025/26 Annual Report, Five-Year Key Figures — dividend per share converted to USD at each year-end rate; retail M and A, payout and leverage targets from the March 2026 strategy update [33] [34].

6. Competitive context — who Sonova actually races

The genuine playing field is a five-manufacturer oligopoly (Sonova, Demant, WS Audiology, GN, Starkey) plus one large pure-play retailer (Amplifon) and the implant specialist (Cochlear Limited). Only three peers are both close matches and present in the filing record; WS Audiology, GN and Starkey are private or absent from the corpus. Benchmark with care — the margin lines below are not strictly comparable (reported EBIT vs adjusted EBITDA), and peer figures stay in each company's reporting currency because cross-currency rates are not in the provided FX table.

Sources: Sonova revenue converted to USD and 22.5% normalized EBITA margin from its FY2025/26 report [35]; Demant revenue DKK 22,971m and 17.2% EBIT margin before special items [36] [37]; Amplifon EUR 2.4bn revenue, 22.6% adjusted EBITDA and 13% share across 5,630 clinics [38] [39]. Cochlear and EssilorLuxottica shown qualitatively.

Three lessons. First, scale at the top is a wash: Sonova (~$4.5bn) and Demant (DKK ~23bn, roughly $3.4bn) are close, so leadership is decided by product cycles, not balance sheets — and right now Sonova is winning that cycle. Second, the retailer earns the best margin: Amplifon's mid-20s adjusted EBITDA is a reminder that the fitting-and-service layer, not the device, is the richest pool — which validates Sonova's push deeper into Retail. Third, Cochlear Limited is the specific threat that matters for the implant segment — Sonova's own filing blames "the largest competitor" for CI share loss in developed markets [40].

7. The ambition — and how to value it

Under a new CEO, Sonova has reset around a clear target: $7.6 billion in revenue by FY2030/31 (from ~$4.5bn), lives improved for 30 million people, and a portfolio refocused on core hearing care [41]. The financial frame behind it: 5–10% local-currency sales CAGR and 7–12% Core EBIT CAGR, built on three priorities — innovate for adoption, win locally with a multi-channel/multi-brand model, and excel in operations [42] [43].

The growth "algorithm" is additive and worth internalizing, because it tells you what has to go right: roughly 3–5 points from underlying market growth, 1–3 points from innovation-and-geography share gains, and 1–2 points from bolt-on retail M and A [44].

Source: March 2026 strategy update — market growth +3–5%, share gains +1–3%, bolt-on M and A +1–2% (chart uses midpoints) [45].

The right lens. Sonova is best underwritten as a cash-compounding medtech — P/E and EV/Core-EBIT through the cycle, not a deep-value or asset play. The value is carried almost entirely by the Hearing Instruments franchise (a ~24% margin, share-gaining, cash-rich business); a clean SOTP would multiple that highly, value Cochlear Implants separately and conservatively as an option on a turnaround, and net off ~$1.3bn of debt. The key swing factors an intelligent investor should watch: (i) whether the Infinio/Sphere cycle keeps driving share before rivals answer; (ii) whether the Cochlear Implants business can stop losing money as the new sound processor ships; and (iii) execution risk around a new CEO, a new regional operating model, and the Consumer Hearing divestment. Buy the compounding engine; price the optionality and the execution honestly.